All In Biotech

Drug Trial Radar · NCT01474161

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Comparative Bioavailability Study of a New GFT505 Formulation With the Existing One After 120 mg Single Oral GFT505 Administration and Assessment of the Gender Effect in Young Healthy Male and Female Volunteers Followed by a Single and Multiple Ascending Dose Safety, Tolerability and Pharmacokinetic Study of GFT505 in Overweight or Obese Subjects and in Diabetic Patients

Last checked: Nov 19, 2026Latest source record: Nov 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

96

Actual

Start

Nov 2011

Primary completion

Nov 2012

Study completion Nov 2012

Sponsor

Lead sponsor
GenfitIndustry
Sponsor type
Industry
Collaborators
SGS Aster S.A.S.; Naturalpha
First posted
Nov 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation (capsule dosed at 20 mg GFT505) in healthy male subjects and to assess the impact of gender on this relative bioavailability after administration in male and female subjects. Using the new formulation, a single and a multiple ascending dose study will be performed in overweight or obese male subjects otherwise healthy whose demographic and physiological characteristics are thought to be closer to those of the target population (Type 2 diabetes). Thereafter, a group of male and female patients with Type 2 diabetes will receive multiple dose administration of GFT505.

Conditions

  • Type 2 Diabetes
  • Diabetes Mellitus, Type 2
  • Metabolic Diseases
  • Cardiovascular Diseases
  • Obese
  • Dyslipidemia

Interventions

  • GFT505 120mg - old formulationDrug

    hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.

  • GFT505 120mg - new formulationDrug

    hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.

  • GFT505 180mg - new formulationDrug

    hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.

  • GFT505 240mg - new formulationDrug

    hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.

  • GFT505 300mg - new formulationDrug

    hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.

  • PlaceboDrug

    hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics parameters (Study Part I)Time frame: 24h post-dose
  2. Safety parameters (Study Parts II, III and IV)Time frame: Part II : 5 days ; Part III : 20 days ; Part IV : 20 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SGS Aster S.A.S. - Phase I Clinical Unit

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.